MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Keywords

Immune systemImmunotherapyAntibodyBladder cancerMonoclonal antibodyMedicineCancerCancer researchAntigenChemotherapyCancer cellCD80ImmunologyCytotoxic T cellBiologyInternal medicineCD40In vitro

Affiliated Institutions

Related Publications

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Sanjeev Mariathasan , Shannon J. Turley , Dorothee Nickles +39 more

Therapeutic antibodies that block the programmed death-1 (PD-1)–programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients with various cancer...

2018 Nature 5078 citations

The biologic importance of tumor‐infiltrating lymphocytes

F. Stephen Hodi , Glenn Dranoff

Detailed pathologic analysis has delineated a close association between intratumoral CD 8 + cytotoxic T cells and favorable clinical outcomes in diverse cancers. Conversely, the...

2010 Journal of Cutaneous Pathology 55 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian , F. Stephen Hodi , Julie R. Brahmer +27 more

Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse...

2012 New England Journal of Medicine 12335 citations

Cancer immunotherapy using checkpoint blockade

Antoni Ribas , Jedd D. Wolchok

The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses i...

2018 Science 6236 citations

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

Charlotte Roach , Nancy Zhang , Ellie Corigliano +7 more

A companion diagnostic assay was codeveloped by Dako for pembrolizumab non–small-cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC). This ...

2016 Applied immunohistochemistry & molecu... 346 citations

Publication Info

Year: 2014
Type: article
Volume: 515
Issue: 7528
Pages: 558-562
Citations: 2392
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2392

OpenAlex

Cite This

APA Style

                            
                                
                                    Thomas Powles, 
                                
                                    Joseph P. Eder, 
                                
                                    Gregg Fine
                                
                                et al.
                            
                            (2014). 
                            MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. 
                            Nature
                            , 515
                            (7528)
                            , 558-562.
                            https://doi.org/10.1038/nature13904
                        

Identifiers

DOI: 10.1038/nature13904